Table 1.
Potential role of biomarkers in cardiovascular and neurological pathologies.
| Biomarker | Cardiovascular Diseases Roles | Neurology Pathologies Roles | |||
|---|---|---|---|---|---|
| Diagnostic | Prognostic | Diagnostic | Prognostic | ||
| Used in Clinical Practice | NT-proBNP | + | + | − | + |
| Troponins | + | + | − | + | |
| CK, CK-MB | + | + | + | + | |
| Galectin-3 | + | + | − | + | |
| Future Potential Use in Clinical Practice | sST2 | + | + | − | + |
| LPC | + | + | − | + | |
| Copeptin | + | + | + | + | |
| S100B | − | + | + | + | |
| MPO | + | + | + | + | |
| GDF-15 | + | + | + | + | |
NT-proBNP—N-terminal pro-natriuretic peptide type B; CK—creatine kinase; CK-MB—creatine kinase isoform MB; sST2—soluble form of the ST2 protein; LPC—Lysophosphatidylcholine; MPO—Myeloperoxidase; GDF-15—Growth differentiation factor-15.